Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact

Tag: Non-Smallž

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
April 2, 2019 Off

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients

By BusinessWire

Analyses include the longest follow-up of lung cancer patients treated with Immuno-Oncology therapy in phase 3 randomized trials PRINCETON, N.J.–(BUSINESS…

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 5, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine